BOSTON, Oct. 27 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced
results of preclinical studies demonstrating that a new class of compounds,
orally available non-antibacterial tetracyclines, has shown promising activity
in a preclinical animal model of multiple sclerosis (MS). Affecting
approximately two million people worldwide, MS is a chronic, inflammatory
condition of the nervous system and the most common non-traumatic neurological
disease in young adults. Dr. David McKenney, a Paratek scientist, will
present the findings during an oral presentation at 2:30 p.m. PST (5:30 p.m.
EST) today at Neuroscience 2004, the Society for Neuroscience's 34th Annual
Meeting in San Diego.
For the first time, Paratek is presenting data showing that its non-
antibacterial tetracycline compounds in a preclinical model of MS have
efficacy comparable to minocycline, an antibiotic also in the tetracycline
family. A previous clinical study directed by Dr. Luanne Metz at the
University of Calgary has demonstrated disease protection in MS patients
treated with minocycline. Unfortunately, long-term treatment with minocycline
or any other broad-spectrum antibiotic causes many patients to experience
intolerability related to antibiotic side effects. In today's presentation,
Paratek will report that three non-antibacterial tetracycline compounds, with
different structures, demonstrated activity in reducing limb paralysis in the
preclinical EAE (Experimental Autoimmune Encephalomyelitis) model of MS.
These compounds have no detectable antibacterial activity.
Paratek Pharmaceuticals, Inc. and Serono (NYSE: SRA; virt-x: SEO)
announced today that they have entered into an agreement to discover, develop
and commercialize an orally available disease-modifying treatment for multiple
sclerosis (MS). The agreement covers the compounds for which Dr. McKenney
presents data today.
Stuart Levy, Paratek's Vice Chairman, Chief Scientific Officer and
Co-Founder, commented, "The clinical research community has long regarded a
pill for MS as an ultimate goal, but so far attempts to develop a safe,
feasible, orally available drug candidate have failed. Our team has
successfully modified the tetracycline molecule, keeping the core structure
that confers anti-MS activity while removing portions of the molecule with
antibacterial effects. This represents an exciting advance not only for MS,
but potentially for many other inflammation-related disease areas."
Dr. Michael Draper, Associate Director at Paratek, stated, "Paratek has
developed world-class expertise in modifying the tetracycline class, which has
a 30-year track record in the marketplace and a favorable, well-documented
safety profile. This new, proprietary class of non-antibacterial tetracycline
compounds will avoid the negative consequences associated with long-term
antibiotic use and will not further contribute to the development of
antibiotic resistance. We believe that these highly active, orally available
compounds will also prove to be well tolerated for MS, and we are very proud
of this accomplishment."
About Multiple Sclerosis
Multiple sclerosis is a chronic, inflammatory condition of the nervous
system and is the most common non-traumatic neurological disease in young
adults. Multiple sclerosis may affect approximately two million people
worldwide. While symptoms can vary, the most common symptoms of multiple
sclerosis include blurred vision, numbness or tingling in the limbs and
problems with strength and coordination. The relapsing forms of multiple
sclerosis are the most common.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is engaged in the discovery and
commercialization of new therapeutics that treat serious and life-threatening
diseases, with a particular focus on the growing worldwide problem of
antibiotic resistance. Paratek's lead programs are advancing novel compounds
that can circumvent or block bacterial resistance, as well as drugs that can
prevent infection by interfering with Multiple Adaptational Response (MAR)
mechanisms in bacteria. Out of these efforts, Paratek has discovered a new
class of antibiotics, the aminomethylcyclines that target the need for new and
potent antibacterials to overcome the problem of rapidly growing bacterial
resistance. The Company's lead antibiotic clinical candidate, BAY 73-7388,
the first product from this class, is being developed in a collaborative
partnership with Bayer HealthCare AG for the treatment of serious infections.
Outside the antibacterial therapeutic area, Paratek has also established
an internal effort to exploit its novel families of compounds and their unique
mechanism of action in selected anti-inflammatory and neurodegenerative
conditions. Paratek has an active chemical synthesis effort to produce novel
and diverse small molecules, with the goal of developing non-antibacterial
products with improved activity in serious diseases based upon a growing body
of clinical and basic research supporting this approach.
Paratek is privately held and headquartered in Boston, Massachusetts, USA.
For more information, visit Paratek's website at http://www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.